Interferon beta 1b (IFN-beta1b)

Jaundice

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3710
R7952		 Fragoso a (control exposed to Glatiramer), 2013 Neonatal jaundice during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 2.06 [0.17;25.26] C
excluded (control group) 		1/10   2/39 3 10
ref
S3712
R7988		 Fragoso a (control unexposed, sick), 2013 Neonatal jaundice during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 1.21 [0.14;10.79] C 1/10   8/95 9 10
ref
Total 1 studies 1.21 [0.14;10.79] 9 10
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fragoso a (control unexposed, sick), 2013Fragoso a, 2013 1 1.21[0.14; 10.79]9100%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.21[0.14; 10.79]910 -NAFragoso a (control unexposed, sick), 2013 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.21[0.14; 10.79]910 -NAFragoso a (control unexposed, sick), 2013 1 Tags Adjustment   - No  - No 1.21[0.14; 10.79]910 -NAFragoso a (control unexposed, sick), 2013 1 All studiesAll studies 1.21[0.14; 10.79]910 -NAFragoso a (control unexposed, sick), 2013 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3710

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.21[0.14; 10.79]910 -NAFragoso a (control unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.06[0.17; 25.26]310 -NAFragoso a (control exposed to Glatiramer), 2013 10.510.01.0